EyePoint, Inc. (ETR:PV3B)
| Market Cap | 26.14M -97.4% |
| Revenue (ttm) | 2.27M -93.9% |
| Net Income | -301.63M |
| EPS | -3.62 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2520 |
| Previous Close | 0.2520 |
| Day's Range | 0.2520 - 0.2520 |
| 52-Week Range | 0.2520 - 0.4200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About EyePoint
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
EyePoint Transcript: UBS Global Biopharma Conference 2026
LUGANO and LUCIA missed their wet AMD primary endpoint, but secondary findings supported continued focus on DURAVYU. Fully enrolled DME Phase III trials are expected to read out together in early Q4 next year, the key near-term catalyst.
EyePoint Transcript: Jefferies Global Healthcare Conference
DURAVYU’s wet AMD Phase III trials missed their primary endpoints, shifting the focus to DME. Management cited Phase II results, repeat-dose safety and a six-month delivery profile as strengths, with pivotal data targeted for early Q4 2027.
EyePoint price target lowered to $5 from $6 at Stifel
Stifel lowered the firm’s price target on EyePoint (EYPT) to $5 from $6 and keeps a Buy rating on the shares.
EyePoint Earnings Call Transcript: Q3 2026
Both phase III wet AMD trials missed their primary endpoint, prompting program discontinuation and a major cost reduction. Focus and cash preservation now center on DME trials, with COMO and CAPRI results expected in early Q4 2027.
EyePoint Earnings release: Q3 2026
EyePoint released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
EyePoint Quarterly report: Q3 2026
EyePoint has published its Q3 2026 quarterly earnings report on November 12, 2026.
EyePoint reports Q3 EPS ($1.07), consensus (93c)
Reports Q3 revenue $756,000, consensus $233,080. “The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable…
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
– Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and m...
EyePoint Transcript: Stifel 2026 Healthcare Conference 2026
COMO and CAPRI are fully enrolled, with DME top-line data expected in early Q4 2027; Phase II results and disease biology underpin management’s optimism. Following wet AMD trial misses, a 53% workforce reduction and $30M in annualized savings are intended to support the DME milestone.
EyePoint Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
LUGANO and LUCIA missed their primary non-inferiority endpoint, although safety, fluid control and injection-burden results were encouraging. COMO and CAPRI are fully enrolled, with both DME readouts targeted for very early Q4 2027.
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint downgraded to Hold from Buy at Jones
Jones analyst Debanjana Chatterjee downgraded EyePoint (EYPT) to Hold from Buy without a price target Duravyu failed to show non-inferiority versus aflibercept in its second Phhase 3 wet age-related m...
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU pati...
EyePoint downgraded to Hold from Buy at Laidlaw
Laidlaw downgraded EyePoint (EYPT) to Hold from Buy without a price target after the second of the two Duravyu in wet AMD Phase III studies failed to meet the primary…
EyePoint price target lowered to $1 from $5 at RBC Capital
RBC Capital analyst Lisa Walter lowered the firm’s price target on EyePoint (EYPT) to $1 from $5 and keeps a Sector Perform rating on the shares. The LUCIA miss was…
EyePoint downgraded to Neutral from Outperform at Mizuho
Mizuho downgraded EyePoint (EYPT) to Neutral from Outperform with a price target of 50c, down from $39. The firm cites the negative Phase 3 LUCIA study results for lead asset…
EyePoint downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded EyePoint (EYPT) to Underweight from Neutral without a price target The firm cites the company’s first Phase 3 trial evaluating Duravyu in wet age-related macul...
Chardan puts EyePoint target under review after trial miss
Chardan notes that EyePoint’s (EYPT) LUCIA trial missed its BCVA non-inferiority primary endpoint, which “closes the wet AMD path.” EyePoint is cutting 53% of its workforce and Duravya in DME…
EyePoint downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded EyePoint (EYPT) to Neutral from Buy with no price target following the second pivotal failure of Duravyu. EyePoint is now focused on DME, but the firm expects investors…
EyePoint downgraded to Hold from Buy at Jefferies
Jefferies analyst Faisal Khurshid downgraded EyePoint (EYPT) to Hold from Buy with a price target of $1, down from $8, after the Phase 3 LUCIA study of Duravyu in wet…
EyePoint price target lowered to $4 from $17 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on EyePoint (EYPT) to $4 from $17 and keeps a Buy rating on the shares after the LUCIA study missed the…
This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.
EyePoint stock is heading for its largest single-day percentage drop on record.
EyePoint Transcript: Study result
LUCIA missed its BCVA non-inferiority endpoint, though DURAVYU improved vision, reduced treatment burden by 38% and showed strong anatomic control with a favorable safety profile. Focus shifts to phase III DME trials, with topline data expected in Q4 2027.
EyePoint Press release: Study result
EyePoint issued a press release on October 19, 2026, disclosing material business information to investors.